A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced or Metastatic Adrenocortical Carcinoma
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Daiichi Sankyo
- Last updated on ClinicalTrials.gov
- May 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Florida Cancer Specialists · Sarasota, FL
New York · 1
- Columbia University · New York, NY
Rhode Island · 1
- Brown University · Providence, RI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.